InflaRx (NASDAQ:IFRX) Share Price Breaks Above 200 Day Moving Average – Should You Sell?

InflaRx N.V. (NASDAQ:IFRX) shares passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.62 and traded as high as $1.66. InflaRx shares last traded at $1.66, with a volume of 513,053 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on IFRX shares. Cantor Fitzgerald boosted their price target on InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a report on Monday, September 21st. Needham & Company LLC began coverage on shares of InflaRx in a report on Monday, September 14th. They issued a “buy” rating and a $8.00 price objective for the company. Finally, Zacks Research lowered shares of InflaRx from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, InflaRx has an average rating of “Moderate Buy” and an average price target of $7.43.

InflaRx Stock Down 0.9%

The company has a market capitalization of $252.74 million, a price-to-earnings ratio of -2.96 and a beta of 2.59. The business has a 50-day moving average price of $1.88 and a 200-day moving average price of $1.62.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). As a group, sell-side analysts predict that InflaRx N.V. will post -0.31 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Sanctuary Advisors LLC purchased a new stake in InflaRx in the 2nd quarter worth about $25,000. AXQ Capital LP purchased a new position in InflaRx during the second quarter valued at approximately $41,000. China Universal Asset Management Co. Ltd. increased its stake in InflaRx by 47.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 23,600 shares of the company’s stock valued at $44,000 after buying an additional 7,600 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of InflaRx in the first quarter worth $142,000. Finally, DCF Advisers LLC purchased a new position in InflaRx in the second quarter valued at about $512,000. 42.39% of the stock is owned by institutional investors and hedge funds.

InflaRx Company Profile

InflaRx N.V. (NASDAQ: IFRX) is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Founded in 2007 and headquartered in Jena, Germany, the company’s research is centered on the complement system, an important part of the immune response. InflaRx seeks to selectively block complement component C5a, a potent inflammatory mediator, while preserving other aspects of immune-system function.

The company’s lead product, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a.